Capivasertib and Fulvestrant for Patients with Aromatase Inhibitor-Resistant HR Positive/her2-Negative Advanced Breast Cancer: Exploratory Analysis of PFS by AKT Pathway Gene from the Phase 3 CAPItello-291 Trial